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Period determination in the mammalian circadian
clock involves the turnover rate of the repressors
CRY and PER. We show that CRY ubiquitination
engages two competing E3 ligase complexes that
either lengthen or shorten circadian period in mice.
Cloning of a short-period circadian mutant, Past-
time, revealed a glycine to glutamatemissensemuta-
tion in Fbxl21, an F-box protein gene that is a paralog
of Fbxl3 that targets the CRY proteins for degrada-
tion. While loss of function of FBXL3 leads to period
lengthening, mutation of Fbxl21 causes period short-
ening. FBXL21 forms an SCF E3 ligase complex that
slowly degrades CRY in the cytoplasm but antago-
nizes the stronger E3 ligase activity of FBXL3 in
the nucleus. FBXL21 plays a dual role: protecting
CRY from FBXL3 degradation in the nucleus and
promoting CRY degradation within the cytoplasm.
Thus, the balance and cellular compartmentalization
of competing E3 ligases for CRY determine circadian
period of the clock in mammals.
INTRODUCTION
In mammals, the circadian clock regulates daily oscillations in
behavior, physiology, and metabolism (Bass and Takahashi,
2010; Mohawk et al., 2012). The mechanism of the circadian
clock is composed of an autoregulatory transcriptional network
(Lowrey and Takahashi, 2011). At the core, the transcription
factors CLOCK and BMAL1 drive expression of the Period
(Per) 1/2 and Cryptochrome (Cry) 1/2 genes. PER1/2 and
CRY1/2 proteins in turn interact, translocate into the nucleus,and repress the activity of CLOCK:BMAL1 to inhibit their own
transcription (King et al., 1997; Gekakis et al., 1998; Lee et al.,
2001). Bmal1 expression is also regulated by a secondary feed-
back loop comprised of the nuclear hormone receptors REV-
ERBa/b and the retinoid-related orphan receptors (Preitner
et al., 2002; Cho et al., 2012).
Although the majority of the core clock components have
been identified, the molecular mechanisms that define the peri-
odicity or rate of the circadian clock are still not well understood
(Zheng and Sehgal, 2012). PER and CRY are essential negative
feedback elements of the clock, and the turnover rates of PER
and CRY are correlated with the period length of circadian
rhythms in mutant strains. For example, the Casein kinase 1ε
tau mutation shortens period and destabilizes the PER proteins
by hyperphosphorylation of a phosphodegron site that targets
the PER proteins for ubiquitination by b-TrCP and proteasomal
degradation (Gallego and Virshup, 2007; Meng et al., 2008).
Conversely, mutations in the F-box protein FBXL3 lengthen
period and stabilize the CRY proteins by a reduction in ubiquiti-
nation-mediated proteosomal degradation involving the
SCFFBXL3 ubiquitin ligase complex (Busino et al., 2007; Godinho
et al., 2007; Siepka et al., 2007). Recent work shows that CRY
ubiquitination by SCFFBXL3 is triggered by AMPK-mediated
phosphorylation (Lamia et al., 2009) and reversed by the deubi-
quitinating enzyme USP2a (Tong et al., 2012).
Genetic analysis of PER and CRY suggests that these two
pathways act independently and additively to regulate circa-
dian period in vivo (Maywood et al., 2011). Here, we report
the isolation and positional cloning of a circadian mutant,
Past-time (Psttm), that shortens circadian period and destabi-
lizes CRY proteins during the circadian cycle. We describe
an SCF ubiquitin ligase complex (SCFFBXL21) for the CRY pro-
teins that plays a dual role to attenuate CRY degradation by
SCFFBXL3 in the nucleus and to promote CRY degradation in
the cytoplasm.Cell 152, 1091–1105, February 28, 2013 ª2013 Elsevier Inc. 1091
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Figure 1. Positional Cloning of Past-time and Identification of the Fbxl21 Mutation
(A) Histogram showing circadian period distribution of ENU mutagenized generation 3 (G3) mutant mice in a recessive screen. The shaded area represents the
average period for WT C57BL/6J mice ± three standard deviations. The Past-time (Psttm) founder mouse is indicated by the arrow.
(B) Representative actogramof aWTC57BL/6Jmouse (top). The actogram is double plotted where each horizontal line represents 48 hr of activity. Themicewere
kept on an LD12:12 cycle (represented in the bar above) for the first 7 days and then released into constant darkness for 21 days (indicated by the arrowhead on
the right). Actogram of the Past-time founder G3 mouse (period = 22.91 hr) (bottom).
(C) Period distribution of F2 intercross mice used for genetic mapping. The three panels from top to bottom represent WT, Psttm/+, and Psttm/Psttm mice,
respectively. ANOVA of the period was performed on the three populations of F2 mice (grouped by genotype) (DF = 2; F = 78.80; p = 3.983 3 1029).
(D) Psttm was initially mapped to a 40 Mb region on chromosome 13 between rs13481788 and rs367922 (left). The chromosome 13 schematic lists the markers
used to map Psttm to a smaller genetic interval. Haplotypes of the 78 Psttm/Psttm F2 intercross progeny (156 meioses) are shown on the right. Black boxes
represent C57BL/6J WT alleles, and white boxes represent C3H/HeJ alleles. The number of recombinants per total meioses is indicated to the right of the
haplotype map. Sequencing of Fbxl21 where a single-base change from G to A is indicated by the asterisk (right).
(E) Structural modeling of the FBXL21 LRR3 motif based on the Skp2 structure in WT and mutant proteins. See also Figure S1.RESULTS
Identification of the Past-time mutation
In an ENU mutagenesis screen using C57BL/6J mice (Figure S1
availableonline),we identifiedashort-periodmutantwithaperiod
length of 22.91 hr (Figures 1A and 1B). Crosses with C3H/HeJ
mice produced animals of three phenotypic classes in the F2
generation, indicating that the mutant, named Past-time (Psttm),
was semidominant (Figure 1C). We initially mapped the Psttm
mutation to a 40 Mb region on chromosome 13 (Figure 1D).
Production of additional recombinants further reduced the
interval to 11.4 Mb. This smaller interval contains 167 open
reading frames and no known circadian clock genes. However,
one candidate, Fbxl21, is a paralog of FBXL3 and shares 85%
amino acid sequence similarity (Jin et al., 2004). FBXL3 has
been shown to form a Skp1-Cul1-F-box protein (SCF) E3 ligase1092 Cell 152, 1091–1105, February 28, 2013 ª2013 Elsevier Inc.complex that polyubiquitinates the CRY proteins for degradation
by the proteasome (Busino et al., 2007), and there is evidence
suggesting that FBXL21 is a clock-controlled E3 ligase involved
inovineCRY1degradation (Dardente et al., 2008).Wesequenced
all of the exons of Fbxl21 from Psttm mice and found a single
G-to-A change at nucleotide 787 in exon 5. This mutation cose-
gregated perfectly with the short-period phenotype of Psttm/
Psttmmice (0/156 recombinants; Figure 1D). The point mutation
converts amino acid 149 froma highly conserved glycine to a glu-
tamic acid residuewithin the third leucine-rich repeat (LRR) of the
protein. This G149E mutation is expected to create a charged
protrusion, probably destabilizing the LRR structure (Figure 1E).
The Psttm Mutation Causes Period Shortening
To confirm that Fbxl21 is the causative gene, we gener-
ated transgenic mice expressing the Psttm allele using the
tetracycline-transactivator (tTA) system (Hong et al., 2007).
Three independent tetO::Psttm transgenic lines were crossed
to Scg2::tTA mice in which the Secretogranin-2 promoter
drives tTA expression in the SCN and other brain areas to eval-
uate whether the Psttm allele affects circadian behavior.
Western blot analysis using cerebellum extracts confirmed
that only double-transgenic mice showed mutant protein
expression (Figure S2A). To determine whether Scg2::tTA-
driven PSTTM expression in the brain also shortens free-
running period as seen in Psttm/+ mice (Figure S2B), we
measured their circadian activity rhythms in constant darkness.
Double-transgenic mice displayed short circadian periods
compared with single-transgenic lines (Figures 2A and S2C).
The period shortening was conditional because doxycycline
(Dox) treatment, which represses tTA transgene expression,
restored the period to wild-type (WT) values (Figures 2A and
S2C). Removal of Dox from the drinking water after 4 weeks
of treatment caused the double-transgenic mice to return
to their previous, short free-running periods, confirming that
inducible PSTTM expression was the cause of the short free-
running periods (Figures 2B and S2D). In contrast, overexpres-
sion of WT FBXL21 under the control of the Scg2::tTA driver did
not cause period changes in Scg2::tTA/tetO::Fbxl21 #38 mice
(Figures S2E, S2F, and S2G). Together, these observations
show that conditional expression of the Psttm allele in the
SCN and brain shortens circadian period in vivo, thus verifying
that Fbxl21 is the causative gene. Because transgenic expres-
sion of Psttm in a WT background shortens period and because
the Psttm allele is semidominant, this suggests that Psttm can
act as an antimorphic mutation.
To investigate the effects of Psttm at the cellular and molec-
ular level, we crossed the Psttm mice with mice carrying the
Per2::luc reporter (Yoo et al., 2004) and examined the cir-
cadian rhythmicity in tissue explants from WT and Psttm
homozygous mice (Figure 2C). SCN organotypic cultures from
Psttm mice showed robust rhythms, yet with significantly
shorter periods compared with those of WT SCNs (Figure 2C,
bottom right). Similarly, pituitary explants from Psttm mice
also showed shorter periods than WT explants (Figure 2C,
bottom). Thus, the primary effect of the Psttm mutation on
the circadian clock is period shortening at both behavioral
and molecular levels.
The FBXL3 I364T mutation in Overtime (Ovtm) mutant mice
lengthens period by about 2.5 hr, providing evidence that
CRY stability is important for setting the pace of the clock
(Siepka et al., 2007). Given that both Ovtm and Psttm
correspond to mutations in F-box genes related to CRY
degradation, we created Psttm/Psttm Ovtm/Ovtm double-
mutant mice to assess the genetic interaction of these mutant
alleles (Figures 2D and 2E). While WT mice showed a mean
period of 23.34 hr, Ovtm mice displayed a long period of
26.00 hr. In contrast, Psttm mice exhibited a short period of
22.77 hr. Interestingly, the Ovtm/Psttm double-homozygous
mutant mice displayed a free-running period of 23.16 hr, similar
to that of WT mice and different from the predicted value of
24.4 hr for an additive effect (Table S1). Thus, the Psttm and
Ovtm alleles appear to act in an antagonistic rather than addi-
tive manner.Effects of the Psttm Mutation on Core Clock Gene
Expression
To explore the effects of the Psttm mutation on clock gene
expression, we collected liver and cerebellum samples from
WT and Psttm mice maintained in constant darkness and
measured messenger RNA (mRNA) expression patterns. The
Psttm mutation caused significant elevation of Per1, Per2,
Cry1, and Cry2 transcripts in cerebellum and a moderate eleva-
tion of clock gene transcript levels in liver (Figures 3A and S3A),
perhaps due to lower Fbxl21 expression in liver relative to cere-
bellum (mean Ct value ofWT cerebellum and liver: 27.1 and 31.2,
respectively; Figure S3D shows different levels of endogenous
FBXL21 expression in various mouse tissues). Interestingly, the
levels of several clock-controlled genes, including Rev-erba,
Dec2, and Dbp, were significantly increased in liver (Figure S3A).
Next, we examined the effects of the Psttm mutation on core
clock protein expression in cerebellum and liver. PER1 and
PER2 levels were elevated in the cerebellum of Psttmmice (Fig-
ure 3B), consistent with the observed increase in transcript
levels. Furthermore, Psttm also appeared to advance the phase
of the PER protein rhythm. In contrast, CRY1 protein levels were
not elevated, and CRY2 levels were significantly reduced (Fig-
ure 3B). Consistent with the previously reported rhythmic
Fbxl21mRNA accumulation (Dardente et al., 2008), we observed
a circadian oscillation of FBXL21 protein in the cerebellum of WT
mice. In Psttm mutants, FBXL21 protein levels in cerebellum
were significantly reduced throughout the circadian cycle com-
pared with WT (Figure 3B), suggesting the Psttm mutation
impaired FBXL21 protein stability. In addition, in the liver ofPsttm
mutants, the phase of PER1/2 and CRY1/2 accumulation was
advanced relative to WT (Figure 3C). FBXL21 protein accumula-
tion was also both reduced and phase advanced in Psttm liver.
The reduction in CRY, despite enhanced transcript levels, sug-
gests that the Psttm mutation leads to the destabilization of
CRY protein. In addition, because the expression of FBXL21 is
rhythmic and in phase with that of CRY1/2 (Figure 3B), it is
possible that FBXL21 could exert phase-dependent effects.
To determine whether the Psttmmutation affects CRY expres-
sion in the SCN, we used immunocytochemical quantitation of
SCN sections from WT and Psttm mice. As shown in Figure 3D,
the number of CRY1-positive nuclei was significantly reduced in
SCN from Psttm mice at ZT0, 8, and 12 compared with WT
controls (Figures 3E, S3B, and S3C). Taken together, these
experiments show that the Psttm mutation leads to a general
increase in the RNA expression of CLOCK:BMAL1 target genes,
while at the same time altering the expression of CRY1 andCRY2
proteins and substantially reducing FBXL21 protein levels. The
reduction in CRY, despite enhanced transcript levels, suggests
that the Psttm mutation leads to destabilization of CRY protein.
FBXL21 Stabilizes CRY by Competing against FBXL3
The concomitant reduction of FBXL21 and CRY proteins caused
by the Psttm mutation prompted us to investigate the bio-
chemical interaction between CRY and FBXL21. Coimmunopre-
cipitation (co-IP) assays showed that among the six core
clock proteins in the primary loop (CRY1/2, PER1/2, CLOCK,
BMAL1), only CRY1 and CRY2 were able to interact with both
FBXL21 and PSTTM (Figure S4A). All CRY1 mutants withCell 152, 1091–1105, February 28, 2013 ª2013 Elsevier Inc. 1093
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Figure 2. The Psttm Mutation Shortens Period and Antagonizes the Period-Lengthening Effect of the Ovtm Mutation in FBXL3
(A) Representative actogram of tetO::Psttm #11 single-transgenic mouse (left). Representative actogram of tetO::Psttm #11 transgenic mouse with the Scg2::tTA
driver (right). Arrowheads indicate LD to DD transition. Doxycycline-containing (10 mg/ml) water was administered during the interval indicated by yellow shading
on the actogram.
(B) Free-running periods of single and double-transgenic mice during constant darkness with water (black), Dox (yellow), and water after Dox treatment (gray).
Error bars represent mean ± SEM (tetO::Psttm #11, n = 3; Scg2::tTA/tetO::Psttm #11, n = 5; *p < 0.05, Bonferroni corrected pair-wise comparison).
(C) Representative PER2::LUC bioluminescence recording of SCN and pituitary explants from WT and homozygous Psttm mice. Blue and red traces represent
PER2 rhythm from WT and Psttmmice, respectively. WT SCN mean circadian period: 24.76 hr (n = 6), Psttm SCN mean circadian period: 23.36 hr (n = 6). t test:
*p value 0.0027. WT pituitary mean circadian period: 23.2 hr, n = 6; Psttm pituitary mean circadian period: 22.61 hr, n = 6. t test: **p value 0.0004.
(D) Representative actograms ofWT,Ovtm/Ovtm, Psttm/Psttm, andOvtm/Ovtm Psttm/Psttmmice subjected to the same experimental schedule as in Figure 1B.
(E) Period distribution. The four panels from top to bottom represent WT,Ovtm/Ovtm, Psstm/Psstm, and Ovtm/Ovtm Psttm/Psttmmice, respectively. ANOVA of
the period was performed among the genotype groups. Results: DF = 3; F = 388.507; p = 2.295 3 1051. See also Figure S2 and Table S1.C-terminal domain truncation were coimmunoprecipitated with
both FBXL3 and FBXL21, indicating that FBXL binds to CRY in
the photolyase homology domain of CRY1 (amino acids 1–530)
(Figure S4). Next we expressed the F-box proteins in NIH 3T3
cells and the cell lysates were immunoprecipitated with anti-1094 Cell 152, 1091–1105, February 28, 2013 ª2013 Elsevier Inc.FLAG (FBXL3, FBXL21, PSTTM) or anti-V5 (b-TrCP1) antibodies.
All the F-box proteins, including PSTTM, were found to interact
strongly with native CULLIN1 and SKP1 (the other components
of the SCF complex), indicating that FBXL21 and PSTTM can
form SCF E3 ligase complexes (Figure 4A). Only low levels of
CRY1 coimmunoprecipitated with ectopically expressed FBXL3,
probably due to robust CRY1 degradation. To our surprise,
FBXL21 or PSTTM coimmunoprecipitated much higher levels
of CRY1 compared with FBXL3. The stable binding between
CRY1 and FBXL21/PSTTM differs from the transient E3 ligase-
substrate interaction commonly associated with rapid degrada-
tion seen with FBXL3-CRY. In addition, ectopically expressed
PSTTM and FBXL21 both showed strong affinity toward CRY,
indicating that the mutation does not significantly affect CRY
binding.
To verify the interactions between FBXL21 and CRY1/2 in vivo,
we assessed native protein interactions over the circadian cycle
by immunoprecipitating endogenous FBXL21 proteins from WT
and Psttm liver tissue lysates collected at different circadian
times (Figures 4B and 4C). Levels of coimmunoprecipitated
CRY1/2 showed a circadian rhythm correlated with their periodic
accumulation (Figure 3C) in WT tissue; on the other hand, lower
levels of CRY1/2 were pulled down in Psttm liver, presumably
due to reduced FBXL21 expression (Figure 3C). Next, we com-
pared the potential E3 ligase activity of FBXL3 with that of
FBXL21 and PSTTM in CRY-degradation assays in 293A cells
(Figures 4D, S4B, and S4C). In the absence of ectopic FBXL3
expression, transfected CRY1 had a half-life of 2.1 hr (Figure 4D
and Figure S4C for CRY2). This rapid degradation was reversed
when Cry1 was cotransfected with hFbxl3si RNA, indicating that
endogenous hFBXL3 regulates CRY1-HA degradation in 293A
cells (Figure S4D). As expected, cotransfection of FBXL3 accel-
erated CRY1 degradation (0.75 hr). In contrast, cotransfection of
FBXL21 significantly decelerated CRY1 degradation (12.3 hr).
PSTTM also appeared to slow down CRY1 degradation, but to
a lesser extent than WT FBXL21 (3.7 hr). Because endogenous
hFBXL3 is present, exogenously expressed FBXL21 probably
antagonizes endogenous hFBXL3 to reduce CRY1 degradation.
Since FBXL21 is a less efficient E3 ligase for CRY1 than FBXL3
(Figure 4D), FBXL21 can act antagonistically with FBXL3. In addi-
tion, because PSTTM itself is less stable than WT FBXL21 (Fig-
ure 4E), PSTTM (4 hr) would be expected to antagonize SCFFBXL3
less efficiently than WT FBXL21 (8.6 hr). Next we introduced
the corresponding Psttm mutation into Fbxl3 (G143E) and mea-
sured the effect of themutation onCRY1 degradation and FBXL3
stability (Figure S4B, bottom). The G143E mutation in Fbxl3 did
not alter protein stability or E3 ligase activity of FBXL3. Impor-
tantly, we rule out the possibility of FBXL21 or PSTTM as an
E3 ligase for FBXL3: coexpression of FBXL21 or PSTTM showed
no effects on FBXL3 stability independent of CRY, indicating that
FBXL21 does not decelerate CRY degradation by serving as an
E3 ligase for FBXL3 (Figure S4E).
To test the hypothesis that FBXL21 antagonizes FBXL3, we
performed competition assays for CRY1 degradation in 293A
cells (Figures 4F and S4F). In support of an antagonistic relation-
ship, coexpression of FBXL3 and FBXL21 resulted in an interme-
diate CRY1 half-life (4.4 hr) relative to expression of CRY1 with
either FBXL3 (1.9 hr) or FBXL21 alone (11 hr). Interestingly, in
the presence of FBXL3, PSTTM was less effective in deceler-
ating CRY1 degradation (3 hr) than FBXL21 (4.4 hr). This sup-
ports the conclusion that PSSTM is a less effective antagonist
of FBXL3-mediated CRY degradation than WT FBXL21. Next,
we carried out similar assays using the hypomorphic Ovtmmutant of Fbxl3 to investigate whether the WT-like circadian
periodicity in Ovtm/Psttm compound homozygous mice is
associated with restored CRY degradation rate (Figures 2D
and 2E). Specifically, 293A cells were cotransfected with Cry1
and F-box pairs, Ovtm+Fbxl21, and Ovtm+Psttm. CRY1 degra-
dation was attenuated in the presence of OVTM (4.9 hr; Figures
4F, bottom, and S4G), whereas PSTTM expression in place of
FBXL21 restored CRY1 degradation in the presence of OVTM
(1.6 hr). These changes in CRY1 degradation rate are directly
correlated with the period shortening or lengthening in the Psttm
and Ovtm mouse mutants (Figure 2E), suggesting that the WT
periods of Ovtm/Psttmmice resulted from an antagonistic inter-
action of the two mutations on CRY degradation, in which
impaired CRY degradation in OVTM was rescued in the pres-
ence of PSTTM.
To verify definitively that FBXL21 forms an SCF E3 ligase com-
plex, we performed in vitro ubiquitination assays to examine the
ubiquitination activity of SCFFBXL3, SCFFBXL21, and SCFPSTTM.
CRY1 was efficiently polyubiquitinated in the presence of
SCFFBXL3 complex. Both FBXL21 and PSTTM were able to carry
out CRY1 polyubiquitination but were less active in generating
highly polyubiquitinated forms of CRY compared with FBXL3
(Figure 4G, bottom: long exposure). The observed differences
in CRY ubiquitination processivity by FBXLs paralleled their
effects on CRY degradation (Figure 4D). CRY1 ubiquitination
by SCFFBXL3 was significantly reduced in the presence of
SCFFBXL21 or SCFPSTTM (Figure 4H), suggesting that attenuated
CRY1 degradation in the presence of both FBXL3 and FBXL21
(Figure 4F, top) was due to direct competition between FBXL3
and FBXL21 as CRY1 E3 ligases (Figure 4H). As shown in the
end-point competition assay (Figure S4H), FBXL21 and PSTTM
(to a lesser extent than WT) were able to protect CRY1 from
FBXL3-mediated degradation in a dose-dependent manner,
suggesting direct competition between FBXL3 and FBXL21.
No activity was detected from in vitro ubiquitination assays
using the UBC13/Uev1A E2 ligase required for K63 ubiquitination
(Figure 4I), indicating that FBXL21 is not involved in nonproteo-
lytic K63 ubiquitination and that CRY stabilization (Figure 4D)
does not involve K63 ubiquitination by FBXL21. To confirm these
results in intact cells, we performed ubiquitination assays by
expressing CRY1, the F-box proteins, and ubiquitin (hUb) in
293A cells in the presence of the proteasome inhibitor MG132
(Figure 4J). Consistent with the in vitro assay results, FBXL21
and PSTTM showed significantly attenuated polyubiquitination
activity relative to FBXL3.
Psttm and Fbxl21 Knockdown Differentially Alter
Nuclear and Cytoplasmic CRY Degradation
To determine the allelic nature of the Psttm mutant, we com-
pared the effects of the Psttm mutation with loss of function of
Fbxl21 using small hairpin RNA (shRNA) knockdown of Fbxl21
(shFbxl21) on mPER2::LUC rhythms in mouse embryonic fibro-
blasts (MEFs). Psttm MEFs showed advanced phases with
significantly shorter periods relative to WT MEFs (Figures 5A
and 5D). PSTTM was less abundant than WT FBXL21 in MEFs
from the mPER2::LUC genetic background (Figure 5C, left),
consistent with what we observed in the tissue samples (Figures
3B and 5C), and knockdown efficiently depleted FBXL21 proteinCell 152, 1091–1105, February 28, 2013 ª2013 Elsevier Inc. 1095
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(Figure 5C, right). Importantly, Fbxl21 knockdown also elicited
phase-advance and period-shortening phenotypes compared
with shRNA control MEFs (Figures 5B and 5D), indicating that
the Psttm allele behaves as either a loss-of-function hypomor-
phic allele or a dominant-negative antimorphic allele. This is
consistent with the in vitro ubiquitination assays that show that
SCFPsttm also does not show a significant gain of function in
ubiquitination activity relative to SCFFBXL21.
To investigate the cellular localization of Fbxl21 and Psttm
action on CRY abundance, we prepared nuclear and cyto-
plasmic fractions from samples collected over the circadian
cycle and assessed CRY levels (Figures 5E, 5F, S5A, and
S5B). InPsttmMEFs, nuclear CRY1 and CRY2 levels were signif-
icantly lower than in WT (Figures 5E, top right, and CRY2 results
are shown in Figure S5A). In contrast, cytoplasmic CRY levels
were significantly elevated in Psttm MEFs throughout the cycle
(Figure 5E, bottom right, and Figure S5A). In a similar manner,
Fbxl21 knockdown reduced nuclear CRY1/2 (Figure 5F, top
right, and Figure S5B) compared to GFP control yet enhanced
cytoplasmic CRY1/2 levels (Figure 5F, bottom right, and Fig-
ure S5B). To understand the mechanism underlying the differen-
tial effects of FBXL21/PSTTM on nuclear and cytoplasmic CRY
levels, we compared the rate of CRY degradation in nuclear
and cytoplasmic fractions from WT versus Psttm MEFs and
shControl versus shFbxl21 cell lines (Figures 5G and 5H). Both
the Psttm mutation and Fbxl21 knockdown accelerated nuclear
CRY1/2 degradation compared with controls (Figures 5G and
5H), with opposite effects on cytoplasmic CRY degradation.
Endogenous FBXL21 was detected in both nuclear and cyto-
plasmic fractions, and the Psttm mutation impaired FBXL21
accumulation in both subcellular compartments (Figure 5G).
Neither the Psttm mutation nor depletion of endogenous
FBXL21 had any effect on nuclear FBXL3 protein levels (Fig-
ure S5C). Together, these findings demonstrate that reduced
levels of FBXL21 elicited opposing effects on CRY degradation
in the nucleus and the cytoplasm, leading to CRY accumulation
in the cytoplasm but accelerated turnover in the nucleus.
FBXL21 Forms SCF Complexes in the Cytoplasm
To determine the subcellular localization of the FBXL proteins,
we generated fluorescent protein fusions of the FBXL proteins.
Consistent with previous results (Cenciarelli et al., 1999),
Venus-FBXL3 localized primarily to the nucleus (Figure 6A). On
the other hand, Venus-FBXL21 was found in both the nucleus
and the cytoplasm (Figure 6A), in accordance withMEF-fraction-
ation experiments (Figure 5G). Venus-PSTTM showed a sub-
cellular distribution similar to WT FBXL21, and Venus-CRY1Figure 3. Psttm Alters Circadian Clock Gene Expression in Mice
(A) Real-time RT-PCR analysis of clock gene expression in WT and Psttm mice
represent SEM for each time point from four independent replicates. Two-way AN
for Per1 (p < 0.001) and Per2 (p < 0.0001). Cry1 expression shows statistically si
(B and C) Clock protein oscillation in cerebellum (B) and liver (C). Western blott
Representative blots from three independent experiments are shown and quant
represent values fromWTandPsttmmice. Error bars represent SEM (n = 3). In (B),
(p < 0.0001), CRY2 (p < 0.0001), and FBXL21 (p < 0.0001). In (C), two-way ANOVA
(D) Immunohistochemical staining of CRY1 in SCN sections from WT and Psttm
(E) Number of CRY1-positive nuclei in the SCN sections collected from WT and
difference between WT and Psttm mice at ZT0 and ZT12 (***p < 0.001) and ZT8localized primarily in the nucleus as reported previously (Yagita
et al., 2002). Next we used bimolecular fluorescence comple-
mentation (BiFC) to investigate the subcellular localization of
FBXL-CRY1 complexes. Specifically, CRY1-VenC was coex-
pressed with the indicated VenN-FBXLs (Figure 6B), and protein
interaction was measured at the Venus emission wavelength
(528 nm). The CRY1-FBXL3 complex was observed primarily in
the nucleus (90%), whereas CRY1-FBXL21 or CRY1-PSTTM
complexes were found in both the nucleus and cytoplasm.
Furthermore, a three-way competitive BiFC assay (Kerppola,
2006), in which C-terminal Cerulean fused to CRY1 (CRY1-
CerC) was allowed to interact with FBXL proteins fused with
either Ven-N (VenN-FBXLs) or Cer-N (CerN-FBXLs), demon-
strated that FBXL21, and to a lesser degree PSTTM, interact
with CRY1 more strongly than FBXL3 (Figure 6C, bottom:
quantification).
To investigate the cause of the differential effects of FBXL21
depletion on subcellular CRY degradation, we examined SCF
complex formation involving FBXL3, FBXL21, and PSTTM by
using BiFC assays. Ven-C and Ven-N were fused to the N termini
of CULLIN1 or SKP1 and the N termini of FBXL3, FBXL2,1, or
PSTTM, respectively. SKP1-FBXL3 and CULLIN1-FBXL3 com-
plexes were observed primarily in the nucleus (Figure 6D). In
contrast, SKP1-FBXL21, SKP1-PSTTM, CULLIN1-FBXL21, and
CULLIN1-PSTTM complexes were abundant in the cytoplasm
(Figures 6D and 6E). Together, these results demonstrate that
FBXL21 is primarily involved in CRY degradation in the cyto-
plasm and that the unstable Psttm allele or Fbxl21 knockdown
leads to cytoplasmic CRY accumulation. On the other hand,
reduced nuclear FBXL21 levels in Psttm or Fbxl21 knockdown
MEFs reduce the antagonistic effects of FBXL21 against
FBXL3, leading to accelerated CRY degradation in the nucleus.
FBXL3 and FBXL21 Ubiquitinate Distinct Lysine
Residues to Regulate CRY1 Degradation
In order to delineate the mechanism of CRY1 degradation by
FBXL3 and FBXL21, we sought to identify the ubiquitination sites
required for CRY1 degradation by these two F-box proteins.
Initially we chose 18 conserved lysine residues in CRY1 and
CRY2 and converted them individually to arginine to test for
loss of function. No single lysine residue was found to be criti-
cally required for CRY1 degradation in the presence of FBXL3
or FBXL21. Of these individual CRY1 mutants, K107R and
K228R showedmildly impaired degradation by FBXL3. Although
K159R and K308R are not conserved between CRY1 and CRY2,
these sites showed similarity to the consensus sequence of
ubiquitination sites (Catic et al., 2004), and the K159R/K308R. Blue and red circles represent WT and Psttm mice, respectively. Error bars
OVA shows significant statistical differences between WT and Psttmmutants
gnificant difference at CT12 (p < 0.01) between WT and Psttm mice.
ing was performed using total protein extracts with the indicated antibodies.
ification is shown to the right of each representative blot. Blue and red circles
two-way ANOVA shows significant differences betweenWTandPsttm for PER2
shows significant differences betweenWT and Psttm for FBXL21 (p < 0.0001).
mice. Representative images from ZT12 are shown.
Psttm mice at ZT0, 8, and 12. Student’s t test shows statistically significant
(*p < 0.01). Error bars represent mean ± SEM. See also Figure S3.
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(A) Interaction of FBXL proteins with CULLIN1 and SKP1. NIH 3T3 cells were transfected with Flag-Fbxl3, Flag-Fbxl21, Flag-Psttm, and V5-bTrcp1 expression
constructs. Coimmunoprecipitated proteins were analyzed by western blotting with anti-CRY1, anti-CUL1, and anti-SKP1 antibodies. Representative blots from
three experiments are shown.
(B and C) FBXL21 interacts with CRY1 (B) and CRY2 (C) in native extracts in a circadian manner. Liver extracts from CT0 to CT24 were immunoprecipitated (IP)
with an FBXL21 antibody, and western blotting was performed with CRY1 and CRY2 antibodies. Bottom: quantification of coimmunoprecipitated CRY1 and
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double mutation caused mild CRY1 stabilization. These initial
experiments suggested that multiple lysine residues probably
play redundant roles for CRY1 degradation. Thus we also em-
ployed a reverse approach, starting from a degradation-resistant
mutant CRY1, in which all 31 lysine residues were mutated
to arginine (CRY1:R). To determine whether CRY1:R retained
protein-protein interactions comparable to WT CRY1, we first
performed coimmunoprecipitation with FBXL3 and FBXL21. As
shown in Figure 7A, cotransfected FBXL3 immunoprecipitated
low levels of WT CRY1-HA in the absence of MG132, probably
due to active CRY1 degradation. In contrast, CRY1:R efficiently
coimmunoprecipitated with FBXL3; concordantly, the in vivo
ubiquitination assay showed that this mutant was resistant to
FBXL3-mediated ubiquitination (Figure 7A, right). Furthermore,
co-IP with PER2 confirmed that CRY1:R could also interact
with PER2 (Figure 7A, bottom). In addition, reporter assays using
a mPer2 promoter construct, pGL6 (Yoo et al., 2005), demon-
strated that CRY1:R was able to repress CLOCK:BMAL1 trans-
activation of E-box-dependent transcription to a similar extent
as WT CRY1 (Figure 7B). Thus, mutation of all 31 lysine residues
in CRY1 renders it resistant to ubiquitination and degradation but
surprisingly functional in protein interaction and transcriptional
repression assays.
We then used site-directed mutagenesis to generate 31 indi-
vidual lysine revertants from Cry1:R to test for gain of function.
Individual clones were transfected, either alone or cotransfected
with Fbxl3 or Fbxl21 expression constructs, into 293A cells, and
degradation was monitored as above (Figures S6 and S7). An
initial gain-of-function screen revealed six putative FBXL3 target
residues: K68, K189, K277, K456, K585, and K599 (Figure 7F).
Combining the four aforementioned residues from the initial
loss-of-function screen, we generated a panel of ten candidate
lysine revertants from Cry1:R, and degradation of these mutants
in the presence of FBXL3 and FBXL21 is shown in Figure 7C. We
further divided the candidate lysine sites into two groups accord-
ing to their proximity to known CRY1 phosphorylation sitesCRY2 amounts. Error bars representmean ± range (n = 2 experiments). Two-way A
amount of CRY1 coprecipitated with FBXL21 throughout the circadian cycle (p <
(D) Differential effects of FBXL21 and PSTTM on CRY1 stability. 293A cells were
cells were treated with 20 mg/ml cycloheximide and incubated for the indicated
using an anti-HA antibody. Bottom: quantification of the effects of FBXL3, FBX
experiments). Half-life was determined by using nonlinear, one-phase exponen
conditions: p < 0.0001).
(E) The Psttmmutation destabilizes FBXL21. 293A cells were transfected with Fbx
in (D). Error bars represent mean ± SEM (n = 3 experiments). Half-life parameter
(F) Competition between FBXL3 and FBXL21/PSTTM modulates CRY1 degradati
(D). Half-life parameter, K, is significantly different: p < 0.0001. Error bars represe
Ovtm and Fbxl21/Psttm in CRY1 degradation. Cycloheximide treatment and CR
cantly different: p < 0.0001. Error bars represent mean ± SEM (n = 3 experiment
(G) In vitro ubiquitination assay. Sf9 cells were infected with the indicated baculo
antibody. Top shows a short exposure image, and the bracket to the right marks p
to the right marks highly polyubiquitinated CRY1. Results are representative of m
(H) In vitro ubiquitination was performed as indicated in (G). Sf9 cells were infected
Fbxl3+Psttm) attenuated the E3 ligase activity of FBXL3. Results are representat
(I) FBXL3/FBXL21-mediated CRY1 ubiquitination requires Ubc5 as an E2 ligase. T
ubiquitination by FBXL21/PSTTMSCF complex. Bottom: lack of CRY1 ubiquitinat
of three replicates.
(J) 293A cells were cotransfected with Cry1-HA, ubiquitin (hUb-HA) and the indic
harvest. Whole-cell lysates were analyzed by western blotting with an anti-CRY1(Lamia et al., 2009). Cry1:R-6Ks is a six-lysine revertant where
the lysine residues are located close to phosphorylation sites,
whereas Cry1:R-4Ks contains four lysine residues without
nearby phosphorylation sites. As shown in Figure 7C, CRY1-
10K regained FBXL3-mediated degradation, displaying a degra-
dation rate similar to that of WT CRY1 (Figure 7D). Interestingly,
Cry1:R-6Ks displayed a similar degradation rate as Cry1:R-10K,
whereas Cry1:R-4Ks was much more stable. Multiple CRY1
mutants with fewer lysine combinations were more resistant to
FBXL3-mediated degradation than Cry1:R-6Ks. Thus, there are
multiple and redundant potential CRY1 degron sites for FBXL3.
FBXL21 expression showed no effects on the half-life of these
revertant CRYs, indicating that FBXL3 and FBXL21 do not
share ubiquitination sites. Remarkably, similar site mapping for
FBXL21 revealed a single candidate residue, K11 (Figure 7E),
as the preferred ubiquitination site for FBXL21 (Figure S7). Fig-
ure 7F shows a summary of results from degron screening. As
indicated by the green boxes, FBXL3 appears to utilize multiple
lysine residues for CRY1 degradation. In contrast, FBXL21
showed a highly restricted preference for CRY1 ubiquitination,
perhaps explaining why FBXL21 displayed low activity in CRY
degradation.
DISCUSSION
CRY proteins are the major negative regulators in the core loop
of the mammalian circadian clock. Multiple lines of evidence
suggest a key role for CRY1 in regulating circadian period length.
For example, impaired CRY degradation in the Ovtm mutant
caused significant repression of CLOCK:BMAL1-driven tran-
scription and lengthening of period (Siepka et al., 2007). In addi-
tion, it has been known for more than a decade that the Cry1
knockout mouse has a short period while the Cry2 knockout
has a long period (van der Horst et al., 1999; Vitaterna et al.,
1999). Recent work has provided insight into the transcriptional
regulation of Cry1 (Ukai-Tadenuma et al., 2011), as well asNOVA shows statistically significant differences betweenWT andPsttm for the
0.0001).
cotransfected with indicated constructs. Thirty-two hours after transfection,
time before harvest. Western blotting was performed to monitor CRY1 levels
L21, and PSTTM on CRY1 stability. Error bars represent mean ± SEM (n = 3
tial decay analysis (half-life parameter, K, is significantly different in all four
l21-Flag or Psttm-Flag constructs. Cycloheximide treatment was performed as
, K, is significantly different: p = 0.0436.
on. Cycloheximide treatment and CRY1 western blotting were performed as in
nt mean ± SEM (n = 3 experiments) (Figure S4F). Bottom: competition between
Y1 western blotting were performed as in (D). Half-life parameter, K, is signifi-
s) (Figure S4G).
virus constructs. Samples were analyzed by western blotting with an anti-Myc
olyubiquitinated CRY1. Bottom shows a long-exposure image, and the bracket
ore than three replicates.
with the indicated baculovirus. Coinfection of Fbxl baculovirus (Fbxl3+Fbxl21,
ive of three replicates.
op: Ubc5-mediated robust ubiquitination by FBXL3-SCF complexes and multi
ion in the presence of Ubc13/Uev1A as the E2 ligase. Results are representative
ated F-box constructs. Cells were treated with MG132 (10 mg/ml) 6 hr before
antibody. Results are representative of three replicates. See also Figure S4.
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identification of a domain in CRY1 that is required for the
maintenance of circadian rhythms (Khan et al., 2012). Despite
these advances, how CRY stability and turnover are regulated
and how CRY stability is related to circadian period remains
to be understood. Here, we identified a short-period mutant,
Past-time, that is caused by a G149E missense mutation in
FBXL21, a leucine-rich repeat F-box protein that is a paralog
of FBXL3, an E3 ligase responsible for CRY protein turnover.
Contrary to working in an additive manner with FBXL3, as might
be expected of a paralog, we find instead that FBXL21 antago-
nizes FBXL3 in genetic interaction experiments in vivo, in cellular
assays of CRY stability, and in biochemical ubiquitination assays
of the reconstituted SCF E3 ligase complex in vitro. Taken
together, these experiments show definitively that FBXL21 inter-
acts with FBXL3 to counterbalance the E3 ligase activity of
SCFFBXL3 on CRY1 and CRY2 to stabilize them, consistent with
the accompanying paper by Hirano et al. (2013) in this issue of
Cell. The mechanism by which FBXL21 protects CRY is unusual
for an E3 ligase. Although FBXL21 has intrinsic E3 ligase activity
as an SCFFBXL21 complex, it is much less efficient than SCFFBXL3
in polyubiquination of CRY but has greater affinity for CRY, as
measured in vivo with competitive BiFC assays. Thus, FBXL21
interacts more strongly with CRY than FBXL3 and, as a conse-
quence, can protect CRY from SCFFBXL3 activity.
From subcellular localization experiments, we found that
the distributions of FBXL21 and FBXL3 are strikingly different:
FBXL3 is found almost exclusively in the nucleus, while
FBXL21 is distributed in both nucleus and cytoplasm. The distri-
bution of the FBXL proteins was also mirrored by their interac-
tions with SKP1 and CULLIN1 so that SCFFBXL3 complexes
were primarily nuclear whereas SCFFBXL21 complexes were
mainly cytoplasmic. Based on the subcellular distribution of
FBXL21 and FBXL3, we infer that their interactions probably
occur in the nucleus. First, in the Psttm mutant and in Fbxl21
shRNA knockdown experiments, the levels of CRY1 and
CRY2 are lower in the nucleus under conditions where either
PSTTM is destabilized or FBXL21 is depleted. Second, theFigure 5. The Psttm Mutation Is Mimicked by Fbxl21 Knockdown and
lization in the Cytoplasm
(A) Psttm shortens circadian period in MEFs. Representative PER2::LUC biolumi
(B) Fbxl21 knockdown shortens circadian period in MEFs. Representative PER2::
infected PER2::LUC MEFs.
(C) Western blotting of WT, Psttm, Lenti-GFP, and Lenti-Fbxl21sh cell lysates sh
MEFs. Filled and open arrows indicate FBXL21 and a nonspecific band, respect
(D) Average period values of the experimental groups in (A) and (B). Statistically
Psttm (23.1 hr, n = 6) MEFs (t test: *p < 0.001,). Likewise, statistically significant di
Fbxl21si (22.68 hr, n = 6) MEFs (t test: *p < 0.001). Error bars represent mean ± S
(E) The Psttmmutation decreases nuclear CRY1 levels and oscillation amplitude.W
Right: quantification from triplicates including examples shown here. CRY1 levels
relative to CRY1 from WT nuclei. In contrast, cytoplasmic CRY1 levels from Psttm
ANOVA, p < 0.001). Error bars represent mean ± SEM (n = 3).
(F) Fbxl21 depletion reveals that Psttm behaves as either a loss-of-function or
Fbxl21sh-infected mPER2::LUC MEFs were treated the same as in (E). Right: qua
mean ± SEM (n = 3). CRY1 levels in Lenti-Fbxl21sh nuclei were significantly reduc
throughout the circadian cycle (p < 0.001).
(G) Accelerated nuclear CRYdegradation and decelerated cytoplasmic CRY degra
using anti-CRY1, -CRY2, and -FBXL21 antibodies for nuclear and cytoplasmic fr
(H) Quantification of nuclear and cytoplasmic CRY1 and CRY2 degradation in Pst
blots shown in (G). Error bars represent mean ± SEM (n = 3). See also Figure S5half-lives of CRY1 and CRY2 are shorter in the nucleus. These
results are consistent with a model in which FBXL3 is a primary
E3 ligase for CRY in the nucleus and FBXL21 protects CRY
from rapid polyubiquitination by SCFFBXL3 by competing with
FBXL3. In the absence of FBXL21, CRY would then be more
susceptible to SCFFBXL3 and would turn over faster to shorten
circadian periodicity. Interestingly, FBXL21 does have modest
E3 ligase activity so that the SCFFBXL21 complex is not inactive,
but is significantly less active than that of SCFFBXL3. Thus, the
antagonistic activity of FBXL21 is most likely to occur mechanis-
tically in a manner analogous to a ‘‘partial agonist’’ in classical
pharmacology where a partial agonist (FBXL21) can act as
a competitive antagonist in the presence of a full agonist
(FBXL3). The evidence that FBXL21 and the SCFFBXL21 complex
display ‘‘partial agonist’’ activity can be seen in the cytoplasmic
effects of loss-of-function mutations of either PSTTM or FBXL21
knockdown where the levels of CRY1 and CRY2 are elevated
significantly. Because there is essentially no FBXL3 in the cyto-
plasm, the SCFFBXL21 complex is the primary E3 ligase for CRY
in the cytoplasm.
Here, identification of the E3 ligase FBXL21 reveals a mecha-
nism involving two paralogous E3 ligases regulating nuclear
CRY protein turnover in an antagonistic manner. Previous work
has provided examples of multiple E3 ligases coregulating a
single target in the cell cycle (Reed, 2003; Pines, 2011). For
example, turnover of the key cell-cycle regulator MYC has
been shown to be regulated by distinct E3 ligases, such as
SCFFBW7, SCFSKP2, and SCFbTrCP, at various cell-cycle phases
(Popov et al., 2010). Additionally, p53 protein degradation also
appears to involve several E3 ligases including Mdm2, ARF-
BP1, PIRH2, COP1, and WWP1 (Dai and Gu, 2010). Importantly,
SCFbTrCP and WWP1 have been shown to confer substrate-
protective functions for MYC and p53, respectively. However,
unlike any of these precedents for interacting E3 ligases in the
cell cycle, where distinct E3 ligases from different protein fami-
lies interact, the antagonism of two paralogous SCF complexes
(SCFFBXL3 and SCFFBXL21) in the same pathway is unique.Promotes Accelerated CRY1 Degradation in the Nucleus and Stabi-
nescence recording from WT and Psttm MEFs.
LUC bioluminescence recording from Lenti-GFP-infected and Lenti-Fbxl21sh-
owing that FBXL21 is low in Psttm MEFs and depleted in Fbxl21 knockdown
ively.
significant difference in period was detected between WT (24.4 hr, n = 6) and
fference in period was detected between Lenti-GFP (24.06 hr, n = 6) and Lenti-
EM.
estern blotting for CRY1was performed using nuclear and cytosolic fractions.
from Psttm nuclei were significantly reduced (top, two-way ANOVA, p < 0.001)
were significantly elevated throughout the circadian cycle (bottom, two-way
a dominant-negative mutation relative to WT Fbxl21. Lenti-GFP- and Lenti-
ntification from triplicates including example shown in (F). Error bars represent
ed (p < 0.001), whereas cytoplasmic CRY1 levels were significantly increased
dation inPsttm and Fbxl21 knockdownMEFs.Western blotting was performed
actions. Representative blots from three experiments are shown.
tm and Fbxl21shMEFs from triplicate experiments including the representative
.
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Figure 6. Differential Localization of FBXL3 and FBXL21 SCF Complexes in the Nucleus and Cytoplasm
(A) Differential subcellular localization of FBXL3, FBXL21, and PSTTM. Full-length Venus-tagged FBXL3, FBXL21, PSTTM, and CRY1 were expressed in 293A
cells, and percentages of cells with fluorescence signals in nuclei only, cytoplasm only, or both were measured. Whereas FBXL3 (96%) and CRY1 (92%) were
predominantly localized to the nucleus, FBXL21 and PSTTM were found in the both nucleus and cytoplasm with 51% and 54% of cells in the cytoplasm,
respectively. Smaller percentages of cells showed nuclei-only localization (FBXL21: 18%, PSTTM: 12%) or both (FBXL21: 30%, PSTTM: 36%). Green: Venus;
blue: DAPI. Bar graphs show the mean ± SD of three replicate experiments. Two-way ANOVA shows the localization is significantly different, p < 0.0001.
(B) Differential subcellular localization of CRY-FBXL complexes. VenN-tagged FBXL3, FBXL21, and PSTTM formed BiFC complexes with VenC-tagged CRY1 in
293A cells. FBXL3-CRY1 complexes were primarily localized to the nuclei (88%); however, FBXL21-CRY1 (62%) and PSTTM-CRY1 (70%) were distributed in
both nuclei and cytoplasm. Green: Venus; blue: DAPI. Bar graphs show themean ± SD of three replicate experiments. Two-way ANOVA shows the localization is
significantly different, p < 0.0001.
(C) Reciprocal two-color, three-way BiFC competition assays in 293A cells using CRY1-CerC complementation with CerN-FBXL3 + VenN-FBXL21 or
VenN-PSTTM (top) and with VenN-FBXL3 + CerN-FBXL21 or CerN-PSTTM (bottom). FBXL21, and to a lesser degree PSTTM, interact with CRY1 more
strongly than FBXL3 (bottom: quantification). Green: Venus; blue: Cerulean. Bar graphs show the mean ± SEM of three replicate experiments; *p < 0.01,
**p < 0.001, ***p < 0.0001.
(D) FBXL3 and SKP1 form complexes predominantly in the nuclei of 293A cells, whereas FBXL21 and PSTTM interact with SKP1 in the cytoplasm. Bar graphs
show the mean ± SD of three replicate experiments. Two-way ANOVA shows the localization is significantly different, p < 0.0001.
(E) FBXL3 and CULLIN1 form complexes mainly in the nuclei of U2OS cells (63%), whereas FBXL21 (75%) and FBXL21Psttm (74%) bind to CULLIN1 mainly in the
cytoplasm. All scale bars represent 30 mm. Bar graphs show the mean ± SD of three replicate experiments. Two-way ANOVA shows the localization is signif-
icantly different, p < 0.0001.Translocation between the cytoplasm and the nucleus is a key
step in the circadian cycles of both the positive factors (CLOCK:
BMAL1) (Kondratov et al., 2003) and the negative factors (CRY/
PER) of the core circadian loop. The subcellular distribution and
relative E3 ligase activity of FBXL3 and FBXL21 create a regula-
tory mode for CRY stability in the cell, analogous to that seen
in the cell cycle where the ubiquitin-proteasomal system can
degrade a specific protein at a specific time and in a specific
place (Pines and Lindon, 2005). Thus, the discovery of FBXL21
and the differential regulation of CRY stability in the nucleus1102 Cell 152, 1091–1105, February 28, 2013 ª2013 Elsevier Inc.and cytoplasm reveal a prominent and sensitive role of the
nucleus in regulating circadian period.
EXPERIMENTAL PROCEDURES
ENU Mutagenesis Screen and Characterization of Psttm
Phenotypes
ENU mutagenesis screen for circadian mutants, genetic mapping, and posi-
tional cloning was performed as described previously (Siepka et al., 2007).
Confirmation of the mutant gene by transgenic expression of the mutant
Psttm allele, Per2::luciferase bioluminescence recording, genetic interaction
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Figure 7. Identification of CRY1 Ubiquitination Sites for FBXL3 and FBXL21
(A) Left: CRY1:R coimmunoprecipited with FBXL3, FBXL21, and PER2. Top: coimmunoprecipitation of CRY1WT and CRY1:R with FBXL proteins. Bottom:
reciprocal co-IP of WT and CRY1:R with PER2. WT or Cry1:R expression constructs were transfected into 293A cells as indicated (+). Right: 293A cells were
cotransfected with indicated constructs. Whole-cell lysates were analyzed by western blotting with an anti-CRY1 antibody. Representative blots from three
experiments are shown.
(B) CRY1:R repressed CLOCK:BMAL1-mediated transcriptional activation of the Per2 promoter. pGL6 was transfected into 293A cells with the indicated
constructs (+). Luciferase reporter assay showed similar repression efficiency for CRY1:R and CRY1 WT. Results are mean ± SEM for three experiments in
duplicate.
(C) Representative western blots of HA-tagged CRY1 (WT, R, R-10Ks, R-6Ks, or R-4Ks). The Cry1 construct was transfected alone or with Fbxl3 or Fbxl21 into
293A cells. Cells were treated with CHX (100 mg/ml) and collected after 0, 3, 6, or 9 hr.
(D) Quantification of CRY1 and CRY1 mutant degradation by Fbxl3 or Fbxl21 from two experiments in duplicate (n = 4 western blots; representative blots
shown in C). Data represent mean ± SEM for expression of Cry1 alone (blue), Cry1 + Fbxl3 (green), or Cry1 + Fbxl21 (orange). Half-life was determined by
nonlinear, one-phase exponential decay analysis. CRY1 half-life: alone, 5 hr; + Fbxl3, 0.7 hr; and + Fbxl21, 9 hr. CRY1:R half-life: alone, > 24 hr; + Fbxl3, 21 hr;
(legend continued on next page)
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experiments, and circadian gene expression analysis are described in the
Extended Experimental Procedures. All animal care and experimental treat-
ments were in accordance with Northwestern University and UT Southwestern
Medical Center guidelines for animal care and use.CRY Degradation, In Vitro Ubiquitination Assays, and Subcellular
Localization
The interaction of FBXL proteins with CRY1/2, and the effects of FBXL proteins
on CRY degradation rates were performed as described (Siepka et al., 2007).
CRY1-containing SCF complexes were purified from Sf9 cells (Invitrogen)
using M2 FLAG agarose. Ubiquitination assays for CRY1 were carried out as
described previously (Xu et al., 2009). CRY interaction and degradation assays
were also performed on nuclear and cytoplasmic fractions. BiFC assays were
performed as described (Kerppola, 2006).SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and two tables and can be foundwith this article online at http://dx.doi.
org/10.1016/j.cell.2013.01.055.ACKNOWLEDGMENTS
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